<div><div></div><div>NRx Pharmaceuticals entered into an Underwriting Agreement with BTIG, as representative of the underwriters, for a public offering of 5,714,286 shares of common stock at $3.50 per share. The company expects net proceeds of about $18.8 million, or $21.6 million if the underwriters exercise their 30-day option to purchase up to 857,142 additional shares. The offering was made off an effective shelf registration statement and closed on June 4, 2026. Directors and officers agreed to a 60-day lock-up.Agreement details:<ul><li>Agreement type: Underwriting agreement for public offering of common stock</li><li>Counterparty: BTIG, as representative of the underwriters</li><li>Signed / Effective: Jun 03 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Raise capital for operations and corporate purposes</li></ul>Original SEC Filing: NRX Pharmaceuticals, Inc. [ NRXP ] - 8-K - Jun. 04, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

NRXP

NRx Pharmaceuticals priced a $3.50 per share stock offering, raising approximately $18.8 million in net proceeds. BTIG led the underwriting of 5,714,286 common shares. The transaction, closed on June 4, 2026, allows for up to an additional $21.6 million if the over-allotment option is exercised. Directors and officers agreed to a 60-day lock-up period.

NRx Pharmaceuticals Prices $3.50 Stock Offering to Raise ~$18.8 Million; BTIG Leads